DBV Technologies (DBVT) to Release Earnings on Wednesday

DBV Technologies (NASDAQ:DBVT) is anticipated to release its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect DBV Technologies to post earnings of ($1.45) per share and revenue of $0.7570 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Tuesday, October 28, 2025 at 12:45 PM ET.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings data on Tuesday, October 28th. The company reported ($1.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.25. The business had revenue of $2.77 million during the quarter, compared to analyst estimates of $1.48 million. DBV Technologies had a negative return on equity of 295.58% and a negative net margin of 2,273.91%. On average, analysts expect DBV Technologies to post $-7 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

DBV Technologies Stock Performance

NASDAQ DBVT opened at $14.64 on Monday. The stock has a 50-day simple moving average of $12.00 and a two-hundred day simple moving average of $10.40. The firm has a market capitalization of $434.85 million, a P/E ratio of -2.83 and a beta of -0.45. DBV Technologies has a fifty-two week low of $2.20 and a fifty-two week high of $18.00.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on DBVT. Wall Street Zen lowered DBV Technologies from a “hold” rating to a “sell” rating in a research note on Friday, July 18th. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective (up previously from $16.00) on shares of DBV Technologies in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of DBV Technologies in a research note on Wednesday, October 8th. Finally, Zacks Research upgraded DBV Technologies from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $16.08.

Institutional Investors Weigh In On DBV Technologies

Several institutional investors have recently bought and sold shares of DBVT. Octagon Capital Advisors LP acquired a new stake in DBV Technologies in the 2nd quarter worth about $9,315,000. MPM Bioimpact LLC acquired a new position in shares of DBV Technologies during the 2nd quarter worth approximately $9,649,000. Finally, Adage Capital Partners GP L.L.C. acquired a new position in shares of DBV Technologies during the 2nd quarter worth approximately $9,659,000. 71.74% of the stock is currently owned by institutional investors and hedge funds.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.